Looks like very good times ahead. So many psychological barriers overcome with this deal too - ACR now has cashflow, and another $50m to top up the R&D budget which was down from $30m to about $10m as I understand.
Great business, great model. Conservative and hardworking. Plenty more products in the pipeline (though of course axiron is the flagship.
Good luck to all.
lilly to acquire global license to axiron, page-5
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
